ASMB Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Benzinga

Forecasting The Future: 4 Analyst Projections For Assembly Biosciences

17 days ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Announces Upcoming Investor Conference Participation

17 days ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Announces Upcoming Investor Conference Participation

21 days ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

a month ago - By: Benzinga - Mentions: SPY ARWR CORT QQQ ...

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

3 months ago - By: Yahoo Finance - Mentions: GILD

Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

4 months ago - By: Yahoo Finance - Mentions: GILD

Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes

4 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

4 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

4 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

5 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

5 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

6 months ago - By: Zacks Investment Research - Mentions: TSHA

Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

6 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

6 months ago - By: Zacks Investment Research - Mentions: AMPH

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates

6 months ago - By: Assembly Biosciences, Inc.

New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

6 months ago - By: Zacks Investment Research - Mentions: BBIO

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

8 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

8 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

8 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

8 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

10 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

ASSEMBLY BIOSCIENCES INC (ASMB) Stock News

ASMB Latest News, Press Relases and Analysis